Bimatoprost is a widely used ocular hypotensive agent to treat glaucoma. It lowers intraocular pressure in humans by increasing both pressure-independent (uveoscleral) and pressure-dependent (conventional) aqueous humor outflow. The present study specifically examines bimatoprost effects on the cells that populate human outflow tissues. METHODS. The authors tested for prostamide receptor activation in primary cultures of human trabecular meshwork (TM), Schlemm's canal (SC), and ciliary smooth muscle (CSM) cells using cellular dielectric spectroscopy (CDS). RESULTS. The authors observed that bimatoprost produced an immediate and concentration-dependent increase in cell monolayer impedance for TM, SC, and CSM cells with EC 50 values of 4.3, 1.2, and 1.7 nM, respectively; corresponding to decreased cell contractility. Notably, in TM, SC, and CSM cells, bimatoprost was approximately equipotent to the selective FP receptor agonists fluprostenol and 17-phenyl PGF 2␣ . Bimatoprost effects were insensitive to cholera toxin and pertussis toxin but were abolished by phorbol 12-myristate 13-acetate pretreatment, suggesting Gq-involvement in cell signaling. The effects of bimatoprost on TM and SC cells were inhibited by the prostamide receptor antagonist AGN211334, with IC 50 values of 1.2 and 3.3 M, respectively. Interestingly, AGN211334 behaved as an apparent inverse agonist in CDS assays involving TM cells but as a neutral prostamide antagonist with SC cells. CONCLUSIONS. Taken together, results suggest that bimatoprost specifically activates receptors in both cell types of the human conventional outflow pathway to modify intraocular pressure. However, only TM cell monolayers appear to have autocrine, or agonist-independent, receptor signaling that is sensitive to a prostamide receptor antagonist. (Invest Ophthalmol Vis Sci. 2010;51:5176 -5181 2 PG-F 2␣ drugs lower intraocular pressure by 25% to 30% after 1 week of once-a-day administration without the significant ocular and systemic side effects experienced more frequently with other topical medications.
V ision loss associated with glaucoma is treatable if intraocular pressure (IOP) is lowered sufficiently and maintained over time. 1 Because of safety issues, frequency of the dosing regimen, and their efficacy as ocular antihypertensive agents, prostaglandin (PG)-F 2␣ mimetics have quickly become the medical treatment of choice for managing IOP in glaucoma patients. 2 PG-F 2␣ drugs lower intraocular pressure by 25% to 30% after 1 week of once-a-day administration without the significant ocular and systemic side effects experienced more frequently with other topical medications. 3 Moreover, PGs as a class are much better than other topical glaucoma drugs at controlling diurnal IOP fluctuations, which appear to increase the progression of visual field defects. 4, 5 Early studies on aqueous humor dynamics in monkeys demonstrated that latanoprost, the prototypical FP receptor agonist, lowered IOP exclusively by increasing uveoscleral outflow. 6 -8 Since these initial reports, recent studies indicate that PGs exert a pronounced effect on pressure-dependent (trabecular/conventional) outflow in human volunteers 9, 10 and in perfused human anterior segments. 11, 12 Although the four PGs currently approved as ocular antihypertensive agents (unoprostone, latanoprost, travoprost, and bimatoprost) do not appear to increase conventional outflow in monkeys, a newer, more potent analog (tafluprost) does, increasing conventional outflow by 33%. 13 Thus, a class of drugs originally thought to lower IOP solely by effects on uveoscleral outflow clearly impacts conventional outflow.
The chief cellular mechanisms by which PGs exert their effects on uveoscleral outflow appear to be a result of extracellular matrix remodeling between longitudinal ciliary muscle fiber bundles. Alteration in matrix metalloproteinase secretion and opening of flow pathways increase uveoscleral outflow over time. 14 -19 Interestingly, modified flow pathways in chronically treated monkey eyes are lined by endothelial cells, apparently a result of new, organized outflow channel formation between muscle bundles. 20 In contrast, the mechanism by which PGs increase conventional outflow in humans is not well understood.
Human trabecular meshwork cells express PG-FP receptors, 21 and activation of FP receptors in perfused human anterior segments results in both acute (hours) and chronic (days) modulation of outflow facility. 11, 12 The chronic change appears to correspond to the extracellular matrix remodeling observed in the trabecular meshwork (TM) of monkeys treated with PGs for 1 year 20 and the altered matrix metalloproteinase secretion detected in cultured human TM cells. 17 The acute increase in outflow facility is consistent with decreased contractility of cultured bovine TM cells. 22 Given that previous studies of PG effects on contractility were performed using bovine TM cells and given that Schlemm's canal (SC) cells were not examined, the purpose of the present study was to test the response of PGs on both cell types that populate the human conventional outflow pathway. Using cellular dielectric spectroscopy, we found that bimatoprost significantly increased impedance (an indicator of cell relaxation) of primary cultures of human TM and SC cell monolayers in a receptor-specific manner, suggesting that both cell types mediate effects of PGs on conventional outflow facility.
MATERIALS AND METHODS

Cell Culture
Enucleated human donor eyes and eye tissues were obtained from the Life Legacy Foundation (Tucson, AZ), National Disease Research Interchange (Philadelphia, PA), and Sun Health Research Institute (Sun City, AZ). Schlemm's canal (SC) cells were isolated from conventional outflow tissues of whole human eyes or postpenetrating keratoplasty surgical remnants using a cannulation technique and then were characterized and cultured as previously described. 23 Trabecular meshwork (TM) cells were isolated from human eyes using a blunt dissection procedure followed by extracellular matrix digestion and were characterized and cultured as previously described. 24 Ciliary smooth muscle (CSM) cells were isolated from fetal human eyes using an explant method previously described. 25, 26 Cell isolates were maintained in Dulbecco's modified Eagle's medium (DMEM; low glucose), supplemented with 10% fetal bovine serum, penicillin (100 U/mL), streptomycin (0.1 mg/mL), and glutamine (0.29 mg/mL). One CSM strain (CSM2), four different SC cell strains (SC51, SC55, SC58, SC60) and three TM cell strains (TM86, TM90, TM92) were used in the present study. Cells were isolated from eyes of human donors 3 months (TM86), 4 months (TM90), 38 years (TM92), 66 years (SC51), 29 years (SC55), 34 years (SC58), and 58 years (SC60) of age at the time of death.
Chemicals
AGN211334, U46619, and cicaprost were obtained from Allergan (Irvine, CA). Bimatoprost, fluprostenol, and 17-phenyl PGF 2␣ were purchased from Cayman Chemicals (Kalamazoo, MI). Pertussis toxin, cholera toxin, and phorbol 12-myristate 13-acetate were purchased from Sigma-Aldrich (St. Louis, MO).
Cellular Dielectric Spectroscopy
Cellular dielectric spectroscopy (CDS) is a label-free technology based on the measurement of complex impedance changes (delta Z or dZ). Impedance (Z) is related to the ratio of voltage to current as described by Ohm's law (Z ϭ V/I). To measure the changes in impedance that occur in response to receptor stimulation, mammalian cells are seeded onto a custom 96-well microtiter plate that contains electrodes at the bottom of each well. The label-free, cell-based assay system (CellKey; Molecular Devices, Eugene, OR) supplies a constant voltage, producing a current that at low frequencies flows both around and between cells (extracellular current [Ziec] ) and at high frequencies flows through cells (transcellular current [Zitc] ). On activation of cell surface receptors, signal transduction pathways are initiated, causing morphologic changes. Production of intracellular effectors results in changes in the cellular cytoskeleton that are reflected in changes in the flow of current across and between the cells in the monolayer. This change in the flow of current around and through cells is represented in a single well by an overall change in the impedance of that well. Thus, activation of the cell receptors results in characteristic bioimpedance measurements, indicative of the activation of signaling pathways that are unique to the main subsets of receptors and effectors expressed by that cell type.
For the present study, human cells were seeded onto custom 96-well microplates (CellKey; Molecular Devices) and grown overnight in optimized growth media (DMEM, [low glucose] supplemented with 10% fetal bovine serum, penicillin [100 U/mL], streptomycin [0.1 mg/mL], and glutamine [0.29 mg/mL]) under standard tissue culture conditions. Cell plating density was optimized for each of three cell types used in the present study. Growth media were aspirated, and Hanks HEPES buffer (Invitrogen, Carlsbad, CA) with 0.1% BSA was added to cells to equilibrate for 30 minutes to 1 hour before the start of each experiment. Equilibrated plates of cells were placed onto the label-free, cell-based assay system (CellKey; Molecular Devices), and baseline measurements were made for 2 minutes at 37°C. Using onboard fluidics, ligands (1 pM-1 M) were added to all wells simultaneously while the instrument actively measured the impedance in each well.
Changes in impedance (dZiec) were captured and quantified in real time for 10 minutes immediately after addition of the drug. Kinetic responses for a selected individual well or all wells were recorded. Extracellular current (dZiec) responses were quantified by the instrument software by subtraction of the minimum impedance (MIN) reading from the maximum (MAX) impedance reading. To obtain the specific MAX Ϫ MIN dZiec response, dZiec response in control wells (buffer only) were substracted from the dZiec response in wells from which the compound was added. Then, the specific dZiec was plotted compared with compound concentrations to generate concentration response curves and to calculate EC 50 /IC 50 values. So the dose-response obtained is already the specific impedance changes dZiec in which the nonspecific impedance changes dZiec (background) was subtracted. For this study, each graph represents the mean doseresponse of three independent experiments using two different cell strains. For comparisons between experiments, we normalized each experiment to bimatoprost (our reference agonist), whose maximum signal was recorded at 10 M.
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For competition experiments, cells were pretreated with AGN211334 (10 nM-50 M) for 15 minutes before the addition of bimatoprost. For pathway validation studies, cells were treated overnight with pertussis toxin (10 ng/mL), cholera toxin (20 g/mL) or phorbol 12-myristate 13-acetate (100 nM) to block Gi or Gs and to or desensitize Gq-mediated signaling pathways, respectively.
Filamentous/Globular Actin Assay
The ratio of filamentous actin (F-actin) to globular actin (G-actin) in two different TM cell strains (n ϭ 4) after treatment with drug was determined using a commercially available kit (BK037; Cytoskeleton, Denver, CO). Confluent and mature TM monolayers were serumstarved with HEPES-buffered DMEM for 2 hours and then received 1 M bimatoprost or remained untreated for 30 minutes. Cells were then lysed with F-actin stabilization buffer (50 mM PIPES pH 6.9, 50 mM KCl, 5 mM MgCl 2 , 5 mM EGTA, 5% glycerol, 0.1% Nonidet P-40, 0.1% Triton X-100, 0.1% Tween 20, 0.1% ␤-mercaptoethanol, 0.001% antifoam C, 1 mM ATP, and Roche protease inhibitor cocktail) and centrifuged (100,000g for 60 minutes at 37°C). Some untreated cell lysates received 1 M phalloidin (positive control) before centrifugation. After the supernatant (G-actin) was removed, the pellet (F-actin) was resuspended in an equal volume of ice-cold dH 2 O containing 10 M cytochalasin-D and kept on ice for 1 hour with mixing every 15 minutes to dissociate the F-actin. An equal volume of G-actin and F-actin samples was then solubilized in 4ϫ Laemmli buffer containing 10% ␤-mercaptoethanol, run on a 10% SDS-polyacrylamide gel, and subjected to immunoblot analysis using standard conditions. The blots were incubated with a rabbit anti-actin antibody (1:500) for 1 hour at 25°C. The relative amounts of F-actin and G-actin were determined by densitometry. Only data in which digitized bands that corresponded to actin bands falling in the linear range of the x-ray film were used for analyses. Values obtained were analyzed by a two-tailed, paired Student's t-test assuming unequal variance.
Statistical Analysis
All experiments were performed in duplicate and repeated three times on three different days using two different cell strains. All graphs and data were obtained using computer software (Sigma Plot; Systat Software Inc., San Jose, CA). All the data presented are mean Ϯ SEM of three independent experiments. Results are expressed as percentage of the bimatoprost activity at a concentration of 10 M.
RESULTS
Control experiments were conducted to examine the range of contractile responses of human ocular cells in culture. Thus, increasing concentrations of two PG agonists, U46619 and cicaprost, working at the TP and IP receptors, respectively, were tested using cellular dielectric spectroscopy. Cell responses were monitored in real time over 10 minutes for each drug concentration on initial exposure. Figure 1 shows the differential responses of ciliary smooth muscle (CSM), trabecular meshwork (TM), and Schlemm's canal (SC) cells. All three cell types contracted (indicated by decreased impedance) robustly when treated with U46619 and had similar EC 50s (TM ϭ 7.8 nM; CSM ϭ 12.2 nM; SC ϭ 24.9 nM). Interestingly, SC cells demonstrated the greatest reaction, threefold that of both TM and CSM cells. In contrast, relaxation responses (indicated by increased impedance) of the different cell types to cicaprost treatment were more variable. Cicaprost had very little activity in TM cells while robustly relaxing both CSM and SC cells. Hence, cicaprost had similar EC 50s of 1.9 nM and 3.9 nM, respectively, but produced a greater response in SC cells.
Next, the capacity of three PG/prostamide FP receptor agonists to modify the contractility status of human outflow cells was assessed. Shown in Figure 2 are To determine G-protein coupling, cells were first pretreated overnight with pertussis toxin, cholera toxin, or phorbol ester to inactivate Gi, Gs, or Gq, respectively. Figure 3 shows that all three ocular cell types-CSM, TM, and SC-were insensitive to overnight pretreatment with pertussis toxin or cholera toxin; however, preincubation of cells with phorbol ester completely abolished bimatoprost-mediated changes in cellular impedance. Results suggest Gq controls bimatoprost effects on cell relaxation of conventional outflow cells.
We validated CDS findings using a second method that assessed the contractility status of mature TM cell monolayers in culture. Using biochemical methods to monitor actin polymerization, we observed that bimatoprost (1 M) decreased the ratio of filamentous actin to globular actin compared with vehicle-treated control (0.61 Ϯ 0.20 vs. 0.79 Ϯ 0.26 [mean Ϯ SD]; n ϭ 4; P ϭ 0.03).
Next, increasing concentrations of the prostamide-selective antagonist AGN211334 were applied to cells treated with a single concentration of bimatoprost. Results in Figure 4 show that AGN211334 competitively antagonized bimatoprost effects on cell impedance with IC 50 values of 3.3 and 1.2 M in SC and TM cells, respectively. At concentrations of 10 nM and 100 nM, bimatoprost-mediated effects were completely blocked by AGN211334 in SC and TM cells, respectively. As FIGURE 1. Concentration-response relationships for prostacyclin (cicaprost) and thromboxane-A2 (U46619) analogues on monolayer impedance of human outflow cells using cellular dielectric spectroscopy. Effects of increasing concentrations of cicaprost (E) and U46619 (F) were tested on mature monolayers of CSM, TM, and SC cells isolated from human donor eyes. Data shown are mean Ϯ SEM for three independent experiments using two different cell strains for each cell type. 
DISCUSSION
The present study demonstrates that PG effects on conventional outflow facility likely involve receptor activation in both resident cell types, TM and SC cells, of the conventional outflow tissues. Results show that bimatoprost effects were rapid, changing shape/cell-cell contacts between TM and SC cells within seconds and involving the Gq signaling pathway. Although bimatoprost-mediated responses in both TM and SC were completely blocked by the prostamide-specific antagonist AGN211334, treatment with AGN211334 alone resulted in decreased monolayer impedance only in experiments using TM cells. Hence, monolayers of TM but not of SC cells in culture appeared to have an autocrine prostamide receptorsensitive or constitutive agonist-independent level of signaling. Because of the tissue architecture, directionality of flow patterns, and proximity of TM and SC cells to each other, autocrine and paracrine signaling in the conventional outflow pathway represent efficient communication mechanisms to maintain tissue homeostasis. The observation that AGN211334 treatment decreased baseline impedance values in TM cells suggests that only TM cells were actively releasing endogenous prostamide-receptor sensitive compounds under the conditions of the experiments and that the intended targets were autocrine in nature or paracrine (downstream), including cells in the juxtacanalicular tissue/inner wall region. Alternatively, it may be that TM cells have constitutive receptor activity (agonist-independent receptor activity) sensitive to the prostamide antagonist. Regardless, these findings are consistent with a previous report by our laboratory using another, less sensitive model system showing that AGN211334 behaves as an inverse agonist, decreasing hydraulic conductivity of TM cell monolayers. 11 To our knowledge these two reports are the only demonstrations of inverse agonism activity (or apparent inverse agonism) of conventional outflow pathway cells.
We chose to include CSM cells in the study as a control because of their documented expression of FP receptors and known involvement in PG/prostamide effects on intraocular pressure, predominantly by way of the uveoscleral pathway. Interestingly, we observed that bimatoprost and the two FP agonists tested relaxed CSM cells. Presumably, cell relaxation of the ciliary muscle results in an immediate but transient increase in uveoscleral outflow. However, the magnitude of such an effect is extremely difficult to assess experimentally in   FIGURE 3 . Analyses of G-protein signaling pathway that mediates bimatoprost effects on cell impedance of human outflow cells. Mature monolayers of CSM, TM, and SC cells isolated from human donor eyes were pretreated with cholera toxin (CTX, OE), pertussis toxin (PTX, f), or phorbol ester (PMA, ) before exposure to increasing concentrations of bimatoprost (BIM, ࡗ). Using cellular dielectric spectroscopy, effects of drug combination on cell monolayer impedance was measured. Data shown are mean Ϯ SEM for three independent experiments using two different cell strains for each cell type. FIGURE 5. Concentration-response relationship for AGN211334, a prostamide-sensitive receptor antagonist, on monolayer impedance of human outflow cells using cellular dielectric spectroscopy. Effects of increasing concentrations of AGN211334 on cell impedance of human TM and SC cell monolayers were monitored. Data shown are mean Ϯ SEM for three independent experiments using two different cell strains for each cell type.
FIGURE 4.
Effects of the prostamide-sensitive receptor antagonist AGN211334 on bimatoprost-mediated stimulation of human outflow cell impedance. Using cellular dielectric spectroscopy, effects of AGN211334 on bimatoprost-mediated stimulation of cell impedance of mature monolayers of human conventional outflow cells were tested. TM and SC cells isolated from human donor eyes were pretreated with increasing concentrations of AGN211334 before exposure to 10 nM and 100 nM bimatoprost, respectively. Data shown are mean Ϯ SEM for three independent experiments using two different cell strains for each cell type.
vivo or in situ during this short time frame. Moreover, relaxation of the ciliary muscle should impair the accommodative process, which is much easier to measure. In fact, Kaufman 28 predicted our present findings almost 20 years ago after documenting effects of PG F 2␣ isopropyl ester on intraocular pressure, pupil diameter, and accommodation in monkeys.
The functional EC 50 values obtained for bimatoprost in TM cells, SC cells, and CSM cells are consistent with the presence of a bimatoprost-sensitive receptor population. 29 -33 Bimatoprost in amide form exhibits no meaningful activity at FP receptors, whereas PGF 2␣ and its anionic analogs, such as 17-phenyl PGF 2␣ and fluprostenol, typically have functional EC 50 values in the low nM range. 29, [31] [32] [33] [34] [35] Where prostamide activity coexisted with FP receptor expression in the present study, bimatoprost and anionic PGF 2␣ analogs were essentially equipotent 30 -33 when comparing bimatoprost, fluprostenol, and 17-phenyl PGF 2␣ in CSM cells. In TM and SC cells, bimatoprost was actually more potent than 17-phenyl PGF 2␣ and fluprostenol, respectively. In contrast, the functional EC 50 values obtained for 17-phenyl PGF 2␣ in the rabbit uterus, feline iris, and human ocular cells were essentially the same. 29, 31 Bimatoprost has, however, been reported as slightly more potent than 17-phenyl PGF 2␣ in the feline lung parenchymal assay. 30 The reasons for these differences in potency between cell types and tissues are likely related to their respective PG receptor populations.
The major endogenous PGs are PGD 2 , PGE 2 , PGF 2␣ , PGI 2 , and TxA 2 , and each preferentially interacts with receptor subtypes designated DP, EP, FP, IP, and TP, respectively. 36 There are subdivisions for DP receptors (DP 1 , DP 2 ) and EP receptors (EP 1 , EP 2 , EP 3 , EP 4 ). Adding complexity, receptors exist in living cells as dimers, precoupled to heterotrimeric G proteins. 37 Receptor dimerization facilitates expansion of the ligand recognition site repertoire, which appears essential for PG receptors to recognize nonenzymatically derived PGs from arachidonic acid 38 and the prostamides, which are COX-2-derived products of the endocannabinoid anandamide. 39 Thus, 8-epi PGE 2 , which is formed by the nonenzymatic oxidation of arachidonate, is recognized by a IP/TP receptor heterodimer. 40 The bimatoprost-sensitive prostamide receptor is a heterodimer formed between the wild-type FP receptor and an alternative FP mRNA splicing variant. 33 Bimatoprost-sensitive receptors remain to be fully characterized. There are at least six alternative mRNA splicing variants for the FP receptor, and only the altFP4 isoform has been studied to date. 33 Moreover, interactions of bimatoprost with a lipid-sensitive receptor encoded by an entirely different gene cannot yet be ruled out. For example, anandamide was found to be a naturally occurring mammalian ligand for cannabinoid receptors 41 but was later discovered also to stimulate vanilloid receptors. 42 Thus, mixed interactions of bimatoprost with available target receptors may eventually explain its different functional potencies and tissue specificities, whereas those of 17-phenyl PGF 2␣ remain constant and consistent with interaction with a homogenous receptor population (prostanoid FP).
Our experience shows that the technique of cellular dielectric spectroscopy is a sensitive way to monitor cell relaxation, cell contraction, and changes in cell-cell association to drugs in real time. [43] [44] [45] We were able to obtain full dose-response curves for bimatoprost using CDS compared with only singlepoint resolution using the ratio of filamentous actin to globular actin and hydraulic contractility of TM cell monolayers. The results of the present study are consistent with those of previous reports demonstrating the importance that relaxation of TM cells plays in increasing conventional outflow facility. 46 -49 Treatment with bimatoprost resulted in an increase in impedance, or a relaxation, whereas treatment with AGN211334 resulted in a decrease in impedance, or a contraction. Interpretation of results with SC cells is more difficult because changes in impedance also reflect changes in cell-cell relationships, a likely component that modulates SC monolayer permeability. Interestingly, responses of SC cells to bimatoprost were consistently more robust than those of TM cells by approximately 15%.
Current strategies to increase outflow facility in humans involve the modulation of TM contractility. Inhibition of intracellular kinases such as ROCK with Y-27632 or sequestration of actin monomers with latrunculin-like compounds are two approaches toward this end. The primary concern with these strategies, however, is the lack of specificity given that all cells in the body have ROCK and actin. In contrast, tissue-specific expression of receptors by TM or SC cells that couple to the contractile machinery (or cell-cell associations) represent an alternative and more viable way to regulate outflow facility and to treat ocular hypertension associated with glaucoma.
